We’ve rebranded some of our products, learn more ›

CODEX® is now PhenoCycler, Phenoptics™ is now Phenolmager.

Featured Video

All videos

Akoya: A Look Ahead on the Evolution of Spatial Biology (Peter Miller, PhD | Akoya Biosciences)

How has spatial imaging gone from ‘heroic experiment’ to a must-have tool for a wide range of applications in a variety of labs? Peter Miller, Akoya’s vice president of research and development, walks us through the advancement of single-cell spatial biology tools, how user needs have influenced the evolution, and what the future holds as the technology moves from academic research labs into the clinic.

Quantitative Multiplex Assays for Pan-Cancer Immuno-Oncology Studies (Kathleen Pfaff, PhD | Dana-Farber Cancer Institute)

Could standard mIF assays make spatial biology technology more accessible in the clinic? Dana-Farber scientist Kathleen Plaff talks about how her lab is developing a six-marker pan-cancer panel, ImmunoProfile, to help simplify the characterization of the tumor-immune microenvironment for researchers, as well as a national collaboration to facilitate the incorporation of spatial biology data into immunotherapy trials.

Correlation of Multiplex Immunofluorescence with RNA Sequencing (Zhongmin Xiang, PhD| BostonGene)

What’s it like for a CRO to provide spatial imaging services for a range of customer needs? BostonGene associate director Zhongmin Xiang shares examples of work done in his lab, as well as strategies the lab has developed, from custom panels and lab-developed tests to AI-based analysis tools, RNAseq deconvolution methods, and high-level profiling summaries.

Unveiling the TME in Pancreatic Cancer: Unlocking the Potential of High-Resolution, Spatially Resolved Tissue Analysis (Andressa Dias Costa, MD | Dana-Farber Cancer Institute)

Among the challenges in treating pancreatic cancer is the lack of reliable genomic biomarkers to help select the appropriate treatment. Could high-resolution, spatially resolved tissue analysis help identify targetable pathways that regulate the pancreatic cancer microenvironment, with implications for expanded or more efficient treatment options?

Spatially Resolved Multi-omics Profiling Using DBiT-seq and the PhenoCycler Fusion (Archibald Enninful, PhD Candidate | Yale University)

Spatially resolved transcriptomics of tissue sections enables advances in fundamental and applied biomedical research, and the Fan Lab at Yale University developed microfluidic chips and the DBiT-seq (Deterministic Barcoding in Tissue) protocol to spatially encode mRNAs in various types of tissue. In this video, Archibald Enninful details how the team combined their transcriptome workflow with the PhenoCycler® -Fusion in order to leverage its single-cell resolution and drill deeper into cell populations.

Spatial Biology Speaker Panel

Peter Miller, Akoya’s vice president of research and development, guides the day’s speakers through a series of questions about their experiences working with RNA and spatial biology.

Akoya Biosciences Operations and Manufacturing Center of Excellence

(2 min) Akoya’s new Operations and Manufacturing Center of Excellence was built to meet the growing demand for our spatial biology solutions and the increased utilization of our PhenoCycler®-Fusion and PhenoImager® HT platforms. The 32,000ft² facility includes R&D, manufacturing, quality control, warehouse space, and distribution, enabling better coordination among internal groups and an improved customer experience.

A Spatial Atlas of Triple Negative Breast Cancer in Women of African Ancestry

(15 min) Jasmine Plummer from St. Jude Children’s Research Hospital shares how she and her team have created a spatial atlas using a multiomic (protein + RNA) imaging approach to profile triple negative breast cancer of women with different African Ancestry. Using these data along with clinical information, Dr. Plummer aims to develop a benchmark test to measure and interpret multiomic data at the cellular level to identify this aggressive and early onset disease.

ImmunoPROFILE: A Pan-cancer Tissue Biomarker Test for Immune Profiling at Institutional Scale

(10 min) James Lindsay from the Dana-Farber Cancer Institute presents a groundbreaking project that demonstrates the successful use of a multiplex tissue biomarker test for pan-cancer immune profiling at institutional scale. The assay is being used in an ongoing prospective cohort study to explore immune phenotypes and response to immunotherapy across 15+ cancer types (looking at CD8, PD-1, PD-L1, and FOXP3), with more than 2,000 patient cases analyzed to-date.